Anti mmp13

Western blotting analysis was conducted as previously reported [40 (link)]. Anti-Runx2 (Cat No. WL03358, 1:500, WanleiBio, Shenyang, China), anti-MMP9 (Cat No. WL03096, 1:500, WanleiBio, China), anti-MMP13 (Cat No. WL04694, 1:500, WanleiBio, China), anti-Col10a1 (Cat No. AF6538, 1:500, Beyotime, Shanghai, China), anti-Caspase 3 (Cat No. WL02117, 1:500, WanleiBio, China), anti-Cleaved caspase 3 (Cat No. WL01992, 1:500, WanleiBio, China), anti-β-actin (Cat No. 20536-1-AP, 1:1000, Proteintech, Wuhan, China) primary antibodies were used.

After treatment and detection of total protein concentration with the BCA Protein Assay Kit (Epizyme Bio, Shanghai, China), total proteins were collected from cells for protein blotting experiments [22 (link),46 (link)]. Anti-Notch1 (1:300, Wanlei Bio, Shenyang, China), anti-p-Notch1 (1:300, Wanlei Bio, China), anti-Notch2 (1:300, Wanlei Bio, China), anti-RBPJ (1:1000, Beyotime Biotechnology, Shanghai, China), anti-Runx2 (1:300, Wanlei Bio, China), anti-Col2a1 (1:1000, Beyotime Biotechnology, Shanghai, China), anti-BMP2 (1:300, Wanlei Bio, China), anti-MMP9 (1:300, Wanlei Bio, China), anti-MMP13 (1:300, Wanlei Bio, China), anti-GAPDH (1:1000, Proteintech, Wuhan, China) primary antibodies were used.